Search | Clinical Trials Finder

Conditions: Nasal Obstruction, Chronic Rhinitis
Interventions: Oxymetazoline + Triamcinolone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dry Eye Syndromes
Interventions: dexamethasone intraocular suspension, 9%, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: SR Cornea Consultants; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Sycamore, Illinois

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Interventions: SURF-201, Placebo; Drug
Lead sponsor: Surface Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 10
States / cities: Hemet, California • Murrieta, California • Brooksville, Florida + 7 more

Conditions: Acne Keloidalis Nuchae, NdYag Laser, AKN, Acne Keloidalis, AK, Dermatitis Papillaris Capillitii, Folliculitis Keloidalis Nuchae, Sycosis Nuchae, Acne Keloid, Keloidal Folliculitis, Lichen Keloidalis Nuchae, Folliculitis Nuchae Scleroticans, Sycosis Framboesiformis
Interventions: NdYag Laser(hair removal laser) plus topical corticosteroid, Topical corticosteroid alone; Device · Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Atopic Dermatitis
Interventions: Standard-of-care treatment for AD, Accu-patch pellet; Other · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more

Conditions: Atopic Dermatitis
Interventions: Placebo, Rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Northridge, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Atopic Dermatitis
Interventions: ZPL389 30mg, ZPL389 50mg, TCS and/or TCI; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Litchfield Park, Arizona • Fairborn, Ohio

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Topical corticosteroids; Drug
Lead sponsor: MEDA Pharma GmbH & Co. KG; Industry
Eligibility: 3 Months to 12 Months
Enrollment: 2,418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more

Conditions: Shoulder Pain
Interventions: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide; Drug
Lead sponsor: Injury Care Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Atopic Dermatitis
Interventions: Oregano extract cream, Hydrocortisone; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Atopic Dermatitis
Interventions: Fluocinonide; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glaucoma, Cataract
Interventions: Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: The New York Eye Surgery Center; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Scleral Buckling
Interventions: Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops; Drug
Lead sponsor: Jason Hsu, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 98
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Hemorrhoids
Interventions: Monad 1, Monad 2, Monad 3, Combination - CITI-002 (low dose), Combination - CITI-002 (high dose); Drug
Lead sponsor: Citius Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 16
States / cities: Huntsville, Alabama • Tucson, Arizona • Chula Vista, California + 12 more

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream, TCS; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 5,621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Morrisville, North Carolina

Search by objective public record fields.

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

Effect of Intraoperative Dexamethasone on Post-op Dry Eye

Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects

NdYag Laser for Acne Keloidalis Nuchae

Acupressure in Pruritus for Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

VANOS Cream and Skin Barrier Function

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis